What Extranase Treats: Main Uses and Benefits

The therapeutic use of Extranase is applied across domains where additional symptomatic support is needed for issues driven by inflammation and physical congestion. This medicine is commonly used to help relieve minor pain, swelling, and inflammation.

The preparation is commonly used across conditions presenting with symptoms associated with acute or episodic changes characterized by symptoms related to physical discomfort and fluid accumulation (edema). This often includes scenarios where additional management of discomfort is required for symptoms that may appear suddenly, such as pronounced swelling, supporting the resolution of bruising (hematoma) after a localized injury, and easing discomfort in specific inflammatory contexts.

“The main benefit is assisting the body in clearing this congestion, which contributes to improved comfort during periods of heightened symptoms.”

This supportive role may assist with maintaining functional stability and helps ease the overall symptom load, particularly during periods when symptoms related to inflammatory or irritative states intensify.

---

Quick Fact: Relief for Swelling and Bruising
Primary Symptom Focus	Edema (Swelling), Inflammation, Bruising (Hematoma)
Common Clinical Contexts	Post-traumatic recovery, Postoperative recovery, Symptomatic congestion
Patient Benefit	Supports faster fluid clearance and symptom relief

Regulatory References

1. Health Canada Product Information

Extranase: Official Population Eligibility

Extranase eligibility is strictly defined by regulatory documents, establishing who is permitted to use the medicine and who is excluded or requires conditional use.

Contraindicated Populations

Use is contraindicated (must not be used) in the following groups:

• Children under 6 years of age.
• Patients with a known allergy to the active ingredient (Bromelain) or any other component of the tablet.

Restricted or Conditional Use

Use is not recommended for patients with specific metabolic disorders (Fructose Intolerance, Glucose-Galactose Malabsorption Syndrome, or Sucrase-Isomaltase Deficiency) due to excipient content.

The medicine must be used with caution in the following populations:

• Patients with hepatic problems (liver impairment).
• Patients with renal problems (kidney impairment).
• Individuals with coagulation disorders (clotting issues).
• Women who are pregnant or breastfeeding.

Approved Age Groups

The medicine is documented for use in Adults and Children/Adolescents from 6 to 15 years of age, provided none of the above contraindications or restrictions apply.

Pharmacodynamic Interaction: Coagulation Risk

Co-administration with anticoagulant drugs, such as Warfarin or Heparin, and antiplatelet medicines, including NSAIDs, carries a documented risk of enhanced coagulopathy. This is classified as a use-with-caution interaction due to an additive pharmacodynamic effect that may increase the potential for bleeding or bruising. Regulatory documents note a specific condition-based caution for patients with pre-existing coagulation disorders. No medicine combinations are formally listed as contraindicated in the available regulatory labeling for the oral form.

Pharmacokinetic Interaction: Exposure Modification

A pharmacokinetic interaction is documented to occur with certain antibiotics. Specifically, co-administration with drugs in the Amoxicillin and Tetracycline classes may result in increased systemic exposure and plasma concentrations of the antibiotic. This effect is documented as an exposure-modifying interaction.

Administration-Related Constraints

The official patient information for the medicine specifies that interactions with food, beverages, or herbal products are considered not applicable. Furthermore, regulatory labeling does not include any mandatory time separation requirements for administering Extranase apart from other medicines.

Extranase is a proteolytic enzyme preparation containing bromelain, a mixture of thiol endopeptidases. Its mechanism involves direct enzyme-substrate interaction as a hydrolase, facilitating the cleavage of sulfhydryl groups in specific proteins.

At the cellular level, bromelain acts as a non-selective protease, hydrolyzing various biomolecules including kininogen and fibrin. The hydrolysis of kininogen, a substrate for the kallikrein-kinin system, modulates the local concentration of pro-inflammatory mediators. It also modulates the activity of nuclear factor-kappa B (NF-kappaB), influencing the transcription of pro-inflammatory cytokines such as TNF-alpha and interleukins.

Downstream cascades include modulation of eicosanoid biosynthesis, specifically inhibiting the production of pro-inflammatory prostaglandins. Furthermore, it exhibits fibrinolytic activity by depolymerizing fibrin. System-level physiological consequences arise from the cumulative effect of reduced local pro-inflammatory signaling and enzymatic modification of proteins in the plasma and extracellular matrix.

How to Use Extranase: Administration Guidelines

Extranase is an oral enzyme preparation intended to be used according to specific procedural guidelines. Its administration is structured around the integrity of its gastro-resistant dosage form and a precise daily schedule. The medicine is consistently administered via the oral route.

The dosing schedule for adults is set at three tablets per dose, to be taken three times per day. This establishes a standardized total daily intake. Administration is subject to a timing constraint: the tablets are preferably administered outside of mealtimes (e.g., between meals). This instruction relates directly to the product’s design, ensuring the active enzyme is delivered to the systemic circulation as intended.

A critical procedural condition is that the tablets must be swallowed whole with a small amount of water. To preserve the protective coating, the tablets must not be crushed or chewed. Compromising the gastro-resistant coating interferes with the intended absorption of the product.

For pediatric use, a different regimen is established. Children aged 6 to 15 years are prescribed one tablet per dose, also taken three times per day. The medicine is not recommended for use in children under 6 years of age. Use of Extranase is generally aligned with short-term, acute protocols, and its continued administration is not advised without medical consultation.

Research evidence / Overview of Studies for Extranase

---

Evidence for Use in Acute Recovery from Surgery

Research was conducted into the use of Extranase in adult populations using Randomized Controlled Trials (RCTs) and meta-analyses following minor surgical procedures like wisdom tooth extractions. Studies monitored changes in facial swelling (edema) and postoperative pain intensity. Findings report patterns of change in these symptoms over the short-term, but results were mixed across systematic reviews, and the research base shows heterogeneity in study designs.

Evidence for Use Following Physical Trauma and Injury

The preparation was evaluated in studies relating to physical trauma injuries and their consequences in soft tissues. Research examined outcomes like the objective reduction in swelling and the rate of hematoma resorption (clearance of bruising). Evidence remains limited in this area, as some earlier clinical series lack robust control groups, and findings frequently rely on patient-reported outcomes describing perceived discomfort.

Research Landscape in Chronic Inflammatory Conditions

The preparation was also studied in contexts involving osteoarthritis. This evidence is derived from RCTs and Equivalence Studies that explored outcomes related to joint pain intensity and associated stiffness. The existing evidence is heterogeneous and remains limited. A key limitation is that the preparation is widely studied in a combination product alongside other active ingredients, which makes isolating the specific contribution of Extranase challenging.

Research Gaps and Limitations

Most research was observed in the acute phase of recovery, meaning follow-up durations were limited (typically spanning days to a few weeks). Limited information is available for long-term outcomes or the durability of findings. Furthermore, data for certain groups remain insufficient, including research examining the use of the preparation in children or older adults. The overall consistency of evidence varies across studies, and comparative evidence is often lacking.

Common questions about Extranase (FAQ)

---

Q: How quickly is Extranase supposed to start working?

Official regulatory information does not specify a precise time-to-onset (e.g., in hours) for the medicine. However, the preparation is officially indicated for use in short-term, acute protocols related to swelling and inflammation. Information regarding the appropriate use duration is typically provided by a prescribing professional or pharmacist.

Q: How long does the effect of Extranase usually last?

The duration of action for a single dose of Extranase is not explicitly detailed in the regulatory patient information. The product is intended to be administered as part of a structured daily schedule, and its general use is described in official documents as being for short-term, acute protocols.

Q: Is Extranase suitable for older adults?

Official eligibility documents do not list older adults as a contraindicated population, meaning use is not prohibited. However, reviews of research evidence note that the data available for this specific age group remain insufficient for full conclusions. The lack of specific data means that the decision regarding use may require careful assessment.

Q: Can Extranase be taken with pain relievers like paracetamol or ibuprofen?

Regulatory warnings indicate a risk of enhanced coagulopathy (increased bleeding potential) when Extranase is taken alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. The official interaction information does not explicitly detail a specific interaction or caution with Paracetamol (Acetaminophen).

Q: Are there official warnings about taking Extranase before surgery?

The regulatory documents advise caution for patients with pre-existing coagulation disorders because Extranase influences blood clotting. This potential for enhanced coagulopathy (bleeding risk) is often highly relevant to surgical situations. All decisions regarding pre-operative use are determined by the specific instructions provided by a healthcare team.

Q: Why is Extranase sometimes mentioned for issues other than its main use?

The official regulatory authorization for Extranase is based strictly on evidence for use in supporting the resolution of swelling (edema) and associated inflammation following minor trauma or surgery. Discussions regarding uses beyond the approved indication are outside the defined regulatory scope for this product.

Q: Does Extranase contain any common allergens like gluten or lactose?

According to the official list of excipients, the tablet formulation contains lactose and sucrose, which are types of sugar. The regulatory documents confirm the tablet formulation contains these excipients, which are linked to contraindications for certain hereditary metabolic disorders.

Q: Does Extranase have an effect on the immune system?

The official description of the mechanism of action is reported to involve modulating the body's inflammatory response. It works by influencing specific pro-inflammatory mediators, such as cytokines like TNF-alpha and interleukins, which are components of the immune signalling process.

Q: Are there any specific organs that Extranase is known to affect?

Official warnings recommend caution for individuals with pre-existing problems in the liver (hepatic) or kidneys (renal). This conditional use is noted in the eligibility section of the product information, implying that these organs are relevant to the drug's safety profile.

Q: Is the mechanism of action of Extranase fully understood?

Official regulatory documents provide extensive detail on the known mechanism of action, including how the enzyme works to break down proteins (proteolysis) and influence inflammatory mediators. The regulatory texts do not contain a statement about whether the understanding is 'complete.'

Q: What are the official guidelines regarding maximum duration of use for Extranase?

The official product documentation states that use is aligned with short-term, acute protocols. It is specifically advised that the preparation should not be used for prolonged periods without receiving a medical reassessment or consultation.

Q: What happens if I forget to take a dose of Extranase?

Patient guidance provided in regulatory materials advises against taking a double dose to attempt to make up for a forgotten one. The instruction is to continue the schedule by taking the next scheduled dose at the usual time.

Q: Can taking Extranase affect the results of a blood test?

Because Extranase acts as a fibrinolytic agent (meaning it influences clotting proteins), studies have indicated it can prolong the results of common blood coagulation tests. These include tests such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).

Q: Can Extranase interact with alcohol?

Official regulatory information, including the comprehensive interactions section, does not contain an explicit interaction or warning regarding the use of alcohol while taking Extranase.

Q: Is Extranase considered a prescription-only medicine?

In its main markets of use, Extranase is generally classified by regulatory authorities as a non-prescription medicine. This means the product can typically be obtained without a medical prescription from an authorized pharmacist.

How to Store and Dispose of Extranase

The storage and disposal requirements for Extranase 900 nK (bromelain tablets) are officially regulated to ensure product stability and environmental protection.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30°C (< 30 C).
Protection	Store in the original outer packaging and protect from humidity.
Child Safety	Keep out of the sight and reach of children.

The authorized shelf-life is typically 3 years, and the medicine must not be used after its expiry date.

Disposal Instructions

Unused or expired Extranase must not be thrown away with household waste or via wastewater. Official instructions require individuals to ask a pharmacist to eliminate the product, as this measure contributes to the protection of the environment.